Solubilization and purification of recombinant modified C-reactive protein from inclusion bodies using reversible anhydride modification

Keywords

Recombinant modified C-reactive protein / Inclusion bodies / Citraconic anhydride

References

Abdulla YH, Hamadah K (1981) C-reactive protein in mental illness. Br J Pshchiatr 138:177
Agrawal A, Chakraborty C (2013) Computational analysis of C-reactive protein for assessment of molecular dynamics and interaction properties. Cell Biochem Biophys 67:645-656
Agrawal A, Gang TB, Rusiñ ol AE (2014) Recognition functions of pentameric C-reactive protein in cardiovascular disease. Med Inflamm. doi:10.1155/2014/319215
Black S, Kushner I, Samols D (2004) C-reactive protein. J Biol Chem 279:48487-48490
Calabró P, Willerson JT, Yeh ET (2003) Inflammatory cytokines stimulated C-reactive protein production by human coronary artery smooth muscle cells. Circulation 108:1930-1932
Ciubotaru I, Potempa LA, Wander RC (2005) Production of modified C-reactive protein in U937-derived macrophages. Exp Biol Med 230:762-770
Cook KM, Hogg PJ (2013) Post-translational control of protein function by disulfide bond cleavage. Antioxid Redox Signal 18:1987-2015
Dellisanti CD, Hanson SM, Chen L, Czajkowski C (2011) Packing of the extracellular domain hydrophobic core has evolved to facilitate pentameric ligand-gated ion channel function. J Biol Chem 286:3658-3670
Dong Q, Wright JR (1996) Expression of C-reactive protein by alveolar macrophages. J Immunol. 156:4815-4820
Dong A, Caughey WS, DuClos TW (1994) Effects of calcium, magnesium and phosphorylcholine on secondary structures of human C-reactive protein and serum amyloid P component observed by infrared spectroscopy. J Biol Chem 269:6424-6430
Du Clos TW (2013) Pentraxins: structure, function, and role in inflammation. ISRN Inflamm. doi:10.1155/2013/379040
Eisenhardt SU, Habersberger J, Murphy A, Chen YC, Woollard KJ, Bassler N, Qian H, von Zur Muhlen C, Hagemeyer CE, Ahrens I, Chin-Dusting J, Bobik A, Peter K (2009) Dissociation of pentameric to monomeric C-reactive protein on activated platelets localizes inflammation to atherosclerotic plaques. Circ Res 105:128-137
El Kebir D, Zhang Y, Potempa LA, Wu Y, Fournier A, Filep JG (2011) C-reactive protein-derived peptide 201-206 inhibits neutrophil adhesion to endothelial cells and platelets through CD32. J Leukoc Biol 90:1167-1175
Gabay C, Hushner I (1999) Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 340:448-454
Gewurz H, Zhang X-H, Lint TF (1995) Structure and functions of pentraxins. Curr Opin Immunol 1:54-64
Haider DG, Leuchten N, Schaller G, Gouya G, Kolodjaschna J, Schmetterer L, Kapiotis S, Wolzt M (2006) C-reactive protein is expressed and secreted by peripheral blood mononuclear cells. Clin Exp Immunol 146:533-539
Hirschfield GM, Gallimore JR, Kahan MC, Hutchinson WL, Sabin CA, Benson GM, Dhillon AP, Tennent GA, Pepys MB (2005) Transgenic human C-reactive protein is not proatherogenic in apoliporpotein E-deficient mice. Proc Nat Acad Sci USA 102:8309-8314
Hokama Y, Coleman MK, Reiley RF (1967) Binding properties and specificity of C-reactive protein. Proc Nat Acad Sci USA 57:706-712
Hood W (1977) Causes of multiple abnormal bands in serum protein electrophoresis. Clin Chem 23:1192
Jabs WJ, Theissing E, Nitschke M, Bechtel JF, Duchrow M, Mohamed S, Jahrbeck B, Sievers HH, Steinhoff J, Bartels C (2003) Local generation of C-reactive protein in diseased coronary artery venous bypass grafts and normal vascular tissue. Circulation 108:1428-1431
Ji SR, Wu Y, Potempa LA, Liang Y-H, Zhao J (2006a) Effect of modified C-reactive protein on complement activation: a possible complement regulatory role of mCRP in atherosclerotic lesions. Atheroscler Thromb Vasc Biol 26:935-941
Ji SR, Wu Y, Potempa LA, Qiu Q, Zhao J (2006b) The interactions of low density lipoprotein with different forms of C-reactive protein: implication of an active role of modified C-reactive protein in the pathogenesis of atherosclerosis. Int J Biochem Cell Biol 38:648-661
Ji SR, Wu Y, Potempa LA, Sheng F-L, Zhao J (2007) Membraneinduced structure change and dissociation of C-reactive (CRP): evidence for membrane as a regulator of CRP function. FASEB J 21:284-294
Khan MI, Surolia A (1982) Chemical modification studies on Ricinus communis (Castor Bean) agglutinin. Eur J Biochem 126:495-501
Khreiss T, József L, Hossain S, Chan JSD, Potempa LA, Filep JG (2002) Loss of pentameric symmetry of C-reactive protein is associated with delayed apoptosis of human neutrophils. J Biol Chem 277:40775-40781
Khreiss T, Jó zsef L, Potempa LA, Filep JG (2004a) Conformational rearrangement in C-Reactive Protein is required for proinflammatory actions on human endothelial cells. Circulation 109:2016-2022
Khreiss T, József L, Potempa LA, Filep JG (2004b) Opposing Effects of C-reactive protein isoforms on shear-induced neutrophilplatelet adhesion and neutrophil aggregation in whole blood. Circulation 110:2713-2720
Kinoshita CM, Ying S-C, Hugli TE, Siegel JN, Potempa LA, Jiang H, Houghton RA, Gewurz H (1989) Elucidation of a proteasesensitive site involved in the binding of calcium to C-reactive protein. Biochemistry 28:9840-9848
Kovacs A, Tornvall P, Nilsson R, Tegner J, Hamsten A, Bjorkegren J (2007) Human C-reactive protein slows atherosclerosis development in a mouse model with human-like hypercholesterolemia. Proc Natl Acad Sci USA 104:13768-13773
Krupinski J, Turu MM, Martinez-Gonzalez J, Carvajal A, Juan-Babot JO, Iborra E, Slevin M, Rubio F, Badimon L (2006) Endogenous expression of C-reactive protein is increased in active (ulcerated noncomplicated) human carotid artery plaques. Stroke 37:1200-1204
Kushner I (1982) The phenomenon of the acute phase response. Ann N Y Acad Sci 389:39-48
Kuta AE, Baum LL (1986) C-reactive protein is produced by a small number of normal human peripheral blood lymphocytes. J Exp Med 164:321-326
Laurent P, Potempa LA, Gewurz H, Fiedel BA, Allen RC (1983) The titration curve of native C reactive protein. Electrophoresis 4:316-317
Lei K-J, Liu T, Zon G, Soravia E, Liu T-Y, Goldman ND (1985) Genomic DNA sequence for human C-reactive protein. J Biol Chem 260:13377-13383
Liu J-Z, Wang M (2007) Improvement of activity and stability of chloroperoxidase by chemical modification. BMC Biotechnol 7:23-30
Ma X, Ji S-R, Wu Y (2013) Regulated conformation changes in C-reactive protein orchestrate its role in atherogenesis. Chin Sci Bull 58:1642-1649
Macintyre SS, Schultz D, Kushner I (1982) Biosynthesis of C-reactive protein. NY Acad Sci 1982(389):76-87
Macintyre SS, Kushner I, Samols D (1985) Secretion of C-reactive protein becomes more efficient during the course of the acute phase response. J Biol Chem 260:4169-4173
Marnell L, Mold C, DuClos TW (2005) C reactive protein: ligands, receptors and role in inflammation. Clin Immunol 117:104-111
Means GE, Feeney RE (1971) In chemical modification of proteins. Holden-Day, Inc. San Francisco
Mikolajek H, Kolstoe SE, Pye VE, Mangione P, Pepys MB, Wood SP (2011) Structural basis of ligand specificity in the human pentraxins, C-reactive protein and serum amyloid P component. J Mol Recognit 24:371-377
Morley JJ, Kushner I (1982) Serum C-reactive protein levels in disease. Ann N Y Acad Sci 389:406-418
Motie M, Brockmeier S, Potempa LA (1996) Binding of model soluble immune complexes to modified C-reactive protein. J Immunol 156:4435-4441
Paul A, Ko KW, Li L, Yechoor V, McCrory MA, Szalai AJ, Chan L (2004) C-reactive protein accelerates the progression of atherosclerosis in apolipoprotein E-deficient mice. Circulation 109:647-655
Potempa LA, Maldonado BA, Laurent P, Zemel ES, Gewurz H (1983) Antigenic, electrophoretic and binding alteration of human C-reactive protein modified selectively in the absence of calcium. Mol Immunol 20:1165-1175
Potempa LA, Siegel JN, Fiedel BA, Potempa RT, Gewurz H (1987) Expression, detection and assay of a neoantigen (neo-CRP) associated with a free, human C-reactive protein subunit. Mol Immunol 24:531-541
Potempa LA, Liao HH, Crump B (1999) A mutant protein and methods and materials for making and using it. Patent 5,874,238. Issued Feb 23, 1999
Reznikoff W, Gold L (eds) (1986) Maximizing gene expression. Butterworth Scientific, London
Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH (1997) Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 336:973-979
Samberg NL, Bray RA, Gewurz H, Landay AL, Potempa LA (1988) Preferential expression of neo-CRP epitopes on the surface of human peripheral blood lymphocytes. Cell Immunol 116:86-98
Sanger F, Nicklen S, Coulson AR (1977) DNA sequencing with chain-terminating inhibitors. Proc Natl Acad Sci USA 74:5463-5467
Sattler KJ, Woodrum JE, Galili O, Olson M, Samee S, Meyer FB, Zhu XY, Lerman LO, Lerman A (2005) Concurrent treatment with renin-angiotensin system blockers and acetylsalicylic acid and reduces nuclear factor kappa & #x03B2; activation and C-reactive protein expression in human carotid artery plaques. Stroke 36:14-20
Schwedler SB, Guderian F, Dämmrich J, Potempa LA, Wanner C (2003) Tubular staining of modified C-reactive protein increases with severity of diabetic nephropathy. Nephrol Dial Transpl 18:2300-2307
Schwedler SB, Filep JG, Galle J, Wanner C, Potempa LA (2006) C-reactive protein: a family of proteins to regulate cardiovascular function. Am J Kidney Dis 47:212-222
Shet SM, Madaiah M (1988) Chemical modification studies on a lectin from winged-bean Psophocarpus tetragonolobus (L.) DCI tubers. Biochem J 254:351-357
Shrive AK, Cheetham GMT, Holden D, Myles DAA, Turnell WG, Volanakis JE, Pepys MB, Bloomer AC, Greehhough T (1996) Three-dimensional structure of human C-reactive protein. Nat Struct Biol 3:16-354
Slevin M, Matou-Nasri S, Turu M, Luque A, Rovira N, Badimon L, Boluda S, Potempa L, Sanfeliu C, de Vera N, Krupinski J (2010) Modified C-reactive protein is expressed by stroke neovessels and is a potent activator of angiogenesis in vitro. Brain Pathol 20:151-165
Son YJ, Kim CK, Kim YB, Kweon DH, Park YC, Seo JH (2009) Effects of citrconylation on enzymatic modification of human proinsulin using trypsin and carboxypeptidase B. Biotechnol Prog 25:1064-1070
Tabor S, Richardson CC (1985) A bacteriophage T7 RNA polymerase/promoter system for controlled exclusive expression of specific genes. Proc Nat Acad Sci USA 82:1074-1078
Teupser D, Weber O, Nageswara Rao T, Saaa K, Thiery J, Fehling JH (2011) No reduction of atherosclerosis in C-reactive proteins (CRP)-deficient mice. J Biol Chem 286:6272-6279
Thompson D, Pepys MB, Wood SP (1999) The physiological structure of human C-reactive protein and its complex with phosphocholine. Structure 7:169-177
Tompa P (2012) On the supertertiary structure of proteins. Nat Chem Biol 8:597-600
Vigushin DM, Pepys MB, Hawkins PN (1993) Metabolic and scintigraphic studies of radioiodinated human C-reactive protein in health and disease. J Clin Invest 91:1351-1357
Wang HW, Wu Y, Chen Y, Sui SF (2002) Polymorphism of structural forms of C-reactive protein. Int J Mol Med 9:665-671
Wang M-Y, Ji S-R, Bai C-J, El Kebir D, Li H-Y, Shi J-M, Zhu W, Costantino S, Zhou H-H, Potempa LA, Zhao J, Filep JG, Wu Y (2011) A redox switch in C-reactive protein modulates activation of endothelial cells. FASEB J 25:3186-3196
Wilson AM, Swan JD, Ding H, Zhang Y, Whitbourn RJ, Gurry J, Yii M, Wilson AC, Hill M, Triggle C, Best JD, Jenkins AJ (2007) Widespread vascular production of C-reactive protein (CRP) and a relationship between serum CRP, plaque CRP and intimal hypertrophy. Atherosclerosis 191:175-181
Wong SH (2000) In chemistry of protein conjugation and crosslinking. CRC Press, Inc. Ann Arbor Woo P, Korenberg JR, Whitehead AS (1985) Characterization of genomic and complementary DNA sequence of human C-reactive protein, and comparison with the complementary DNA sequence of serum amyloid P component. J Biol Chem 260:13384-13388
Wu Y, Ji SR, Potempa LA, Filep JG (2007) Structural transition from pentamer to monomer: a mechanism for regulation of C-reactive protein bioactivities. Atheroscler Comment. www. athero.org/commentaries/comm537.asp
Yasojima K, Schwab C, McGeer EG, McGeer PL (2001) Generation of C-reactive protein and complement components in atherosclerotic plaques. Am J Pathol 158:1039-1051
Ying S-C, Gewurz H, Kinoshita CM, Potempa LA, Siegel JN (1989) Identification and partial characterization of multiple native and neoantigenic epitopes of human C-reactive protein using monoclonal antibodies. J Immunol 143:221-228
Ying S-C, Shephard E, deBeer FC, Siegel JN, Harris D, Gewurz BE, Fridkin M, Gewurz H (1992) Localization of sequencedetermined neoepitopes and neutrophil digestion fragments of C-reactive protein utilizing monoclonal antibodies and synthetic peptides. Mol Immunol 29:677-687
Zhu L, Chen L, Zhou XM, Zhang YY, Zhang YJ, Zhao J, Ji SR, Wu JW, Wu Y (2011) Structural insights into the architecture and allostery of full-length AMP-activated protein kinase. Structure 19:515-522
Zouki C, Haas B, Chan JCD, Potempa LA, Filep JG (2001) Loss of pentameric symmetry of C-reactive protein is associated with promotion of neutrophil-endothelial cell adhesion. J Immunol 167:5355-5361